Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003557 · ClinicalTrials.gov registry record · Phase 2
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
A Phase 2 study of Liver Cancer and Gallbladder Cancer, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 11
- Study locations
NCT00003557: Completed Phase 2 study of Liver Cancer and Gallbladder Cancer, sponsored by University of Chicago.
NCT00003557 is a Phase 2 study of Liver Cancer and Gallbladder Cancer that has completed, run by University of Chicago. The registered enrollment target is 16 participants, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003557, a Phase 2 study of Liver Cancer and Gallbladder Cancer, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 11
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or recurrent liver, bile duct, or gallbladder cancer.
Conditions Studied
Interventions
- DRUG dolastatin 10
Study Locations (11)
Illinois
- University of Illinois at Chicago - Chicago
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
- Cancer Care Specialists of Central Illinois, S.C. - Decatur
- Evanston Northwestern Health Care - Evanston
- Lutheran General Cancer Care Center - Park Ridge
- Illinois Oncology Research Association - Peoria
- Central Illinois Hematology Oncology Center - Springfield
Indiana
- Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne
- Michiana Hematology/Oncology P.C. - South Bend
Texas
- University of Texas - MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 1999-01 |
| Est. Completion | 2003-08 |
| Phase | Phase 2 |
What the finished NCT00003557 record still lists
NCT00003557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 448-participant average among 78 other Liver Cancer trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which dolastatin 10 is the first listed.
NCT00003557 lists 11 locations in 3 states (Illinois, Indiana, Texas).
Frequently Asked Questions
What is clinical trial NCT00003557 about?
NCT00003557 is a clinical study titled "Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic or recurrent liver, bile duct, or gallbladder cancer.
What is the current status of trial NCT00003557?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 1999-01. Estimated completion is 2003-08.
What conditions does trial NCT00003557 study?
This clinical trial studies the following conditions: Liver Cancer, Gallbladder Cancer, Extrahepatic Bile Duct Cancer.
What interventions are being tested in trial NCT00003557?
The interventions under investigation include: dolastatin 10 (DRUG).
Who is sponsoring clinical trial NCT00003557?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003557 being conducted?
This trial has 11 study locations across Illinois, Indiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003557's enrollment target sits among peer trials
16 68th of 78 higher than 10 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
RECRUITING · Phase 2
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
-
Domvanalimab and Zimberelimab in Advanced Liver Cancers
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia